Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging safety, tolerability and antitumor activity in patients with PDAC harboring a KRAS G12D mutation Company on track to provide update on lung cancer programs in the fourth quarter of 2024 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2024, and provided an update on corporate progress. The company is committed to revolutionizing treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative, targeted medicines across lines of therapy and tumor types. “We've made enormous progress on behalf of patients against this year's strategic prioritie
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at HC Wainwright from $62.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Needham & Company LLC from $61.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $54.00 to $63.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Piper Sandler from $57.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
RVMD
Earnings
- 11/6/24 - Miss
RVMD
Sec Filings
- 11/13/24 - Form 144
- 11/8/24 - Form 4
- 11/8/24 - Form SC
- RVMD's page on the SEC website